Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?

Abstract

Get full access to this article

View all access options for this article.

References

Ference

Ginsberg

Graham

et al.

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459–2472.

Bouhairie

Goldberg

. Familial hypercholesterolemia. Cardiol Clin 2015; 33: 169–179.

Wong

Kruse

Kutikova

et al.

Cardiovascular disease risk associated with familial hypercholesterolemia: A systematic review of the literature. Clin Ther 2016; 38: 1696–1709.

Langsted

Kamstrup

Benn

et al.

High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study. Lancet Diabetes Endocrinol 2016; 4: 577–587.

Franchini

Capuzzo

Liumbruno

. Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): A critical literature review. Blood Transfus 2016; 14: 413–418.

Assmann

Schulte

von Eckardstein

. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179–1184.

Seed

O'Connor

Perombelon

et al.

The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993; 101: 61–68.

Robinson

Farnier

Krempf

et al.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489–1499.

Sabatine

Giugliano

Wiviott

et al.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500–1509.

10.

Julius

. History of lipidology and lipoprotein apheresis. Atheroscler Suppl 2017; 30: 1–8.

11.

Bigazzi F, Sbrana F, Berretti D, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci. Epub ahead of print 1 August 2018. DOI: 10.1016/j.transci.2018.07.015.

12.

Julius

. Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis 2018; 5: pii: E27.

13.

Thompson

Barbir

Davies

et al.

Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208: 317–321.

14.

Catapano

Graham

De Backer

et al.

2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999–3058.

15.

Reiner

. PCSK9 inhibitors–past, present and future. Expert Opin Drug Metab Toxicol 2015; 11: 1517–1521.

16.

Horton

Cohen

Hobbs

. Molecular biology of PCSK9: Its role in LDL metabolism. Trends Biochem Sci 2007; 32: 71–77.

17.

Raal

Panz

Immelman

et al.

Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013; 2: e000028–e000028.

18.

Pećin

Hartgers

Hovingh

et al.

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol 2017; 24: 1383–1401.

19.

Navarese

Kolodziejczak

Schulze

et al.

Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. Ann Intern Med 2015; 163: 40–51.

20.

Sbrana

Dal Pino

Bigazzi

et al.

Statin intolerance in heterozygous familial hypercholesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?

Eur J Prev Cardiol 2017; 24: 1528–1531.

21.

Moriarty

Parhofer

Babirak

et al.

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoproteinapheresis: The ODYSSEY ESCAPE trial. Eur Heart J 2016; 37: 3588–3595.

22.

Zenti

Altomari

Lupo

et al.

From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol 2018; 25: 1843–1851.

23.

Castelli

. Cholesterol and lipids in the risk of coronary artery disease–the Framingham Heart Study. Can J Cardiol 1988; 4: 5A–10A.

24.

Barter

Gotto

LaRosa

et al.

Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301–1310.

25.

Sinzinger

Steiner

Derfler

. Pleiotropic effects of regular lipoprotein-apheresis. Atheroscler Suppl 2017; 30: 122–127.

26.

Stefanutti

Mazza

Pasqualetti

et al.

Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia. Atheroscler Suppl 2017; 30: 200–208.

27.

Strauchmann

Wallbach

Bramlage

et al.

Lipoprotein apheresis reduces biomarkers of plaque destabilization and cardiovascular risk. J Clin Apher 2014; 29: 235–242.

28.

Ridker

Everett

Thuren

et al.

Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.

29.

Ridker

MacFadyen

Everett

et al.

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet 2018; 391: 319–328.

30.

Lappegård

Enebakk

Thunhaug

et al.

Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol. Atherosclerosis 2016; 251: 119–123.

31.

Kawashiri

Nohara

Higashikata

et al.

Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis 2017; 265: 225–230.